Business
GSK Pays Up to $1.3B for HUTCHMED’s Cancer Drug That Hits Two Targets at Once
The deal licenses HMPL-A830, an antibody-delivered therapy designed to shut down both EGFR and KRAS — a driver mutation in many colorectal, lung and pancreatic cancers.